The “Turkish Pharmaceutical Industry Report” prepared by IQVIA with the support of the Association of Research-Based Pharmaceutical Companies (AIFD) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) will guide the healthcare sector.
Türkiye Pharmaceutical Industry Report 2023, prepared by IQVIA under the sponsorship of AIFD and EFPIA, was shared with the public. The report, which examines the Turkish pharmaceutical industry in the light of objective and comparative annual data, includes in-depth current analyzes from global pharmaceutical market sizes to healthcare expenditures, from reimbursement processes to production, foreign trade, investment and R&D areas, which are important components of the pharmaceutical value chain.
A first-of-its-kind report will guide the health sector
Emphasizing that the report presents information and data that is a first for Türkiye, Dr. Ümit Dereli, General Secretary of the Association of Research-Based Pharmaceutical Companies said,
“Turkish Pharmaceutical Industry Report 2023 independently reveals the research, analysis and conclusions of both Türkiye and the world pharmaceutical industry, showing the areas that need improvement, as well as being a guide that will move our industry forward. Within the framework of the report study, our country’s pharmaceutical industry was compared with equivalent countries in many different dimensions and with objective data. In this context, we believe that the report will enable the correct positioning of our pharmaceutical industry. With this report, which we will renew regularly every year and which will, in a sense, become the almanac of our sector, we aim to provide a reference source for all our stakeholders, from the public to the academy and the private sector, while keeping the pulse of our health sector.”
